All studies
Enrolling by invitationOBSERVATIONAL

A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

This study is gathering information on Refixia/REBINYN, a treatment for males with Haemophilia B. We want to understand how it works and if there are any side effects when used over several years. If you join, you'll continue to receive your usual treatment as decided by your doctor. You'll have regular clinic visits just as you do now, where your doctor might check your health and ask about any side effects. You'll also be asked to keep track of any bleeds and your treatment, and to fill out questionnaires about your quality of life and physical activity. Your participation could last for 4 to 9 years, but you are free to leave the study at any time without affecting your medical care.

At a glance

Status
Enrolling by invitation
Sponsor
Novo Nordisk A/S
Enrolment target
60
Start
01 Apr 2019
Estimated completion
15 Dec 2027

What is this study about?

This research study is for males who have Haemophilia B and are being treated with a medicine called Refixia/REBINYN. Haemophilia B is a rare inherited disorder where your blood doesn't clot properly due to a lack of a specific protein called Factor IX. This can lead to longer bleeding after injuries.

The main aim of this study is to collect information on how well Refixia/REBINYN works to prevent bleeds and whether it causes any side effects when used regularly over a long period. We already know this treatment helps, but understanding its long-term effects is very important for patients' health and well-being. This information helps doctors understand the best ways to care for people with Haemophilia B.

By taking part, you'll be contributing to valuable knowledge that could help many other people living with Haemophilia B in the future. The study is designed to fit in with your normal medical care, so it shouldn't feel too different from your usual check-ups.

Key takeaways

  • This study collects long-term information on a Haemophilia B treatment called Refixia/REBINYN.
  • It aims to understand how well the medicine works and if there are any side effects over time.
  • Only males with Haemophilia B already using or starting Refixia/REBINYN can join.
  • You'll continue your usual treatment and have regular check-ups.
  • You'll track bleeds and fill out questionnaires about your quality of life.
  • Participation lasts 4-9 years, with the option to withdraw at any time.

Who may be eligible?

This study is specifically for males of any age who have Haemophilia B and who are already using or are about to start using Refixia/REBINYN as a regular treatment to prevent bleeds. Importantly, the decision to start or continue this particular medicine must have been made by you (or your parent/guardian if you're under 18) and your doctor, completely separate from whether you join this study.

This means if your doctor has already decided that Refixia/REBINYN is the best treatment for you, then you might be able to join. You'll need to be able to understand what the study involves and agree to take part by signing a consent form.

You won't be able to join if you've already taken part in this specific study before. Also, if you're known to be allergic to Refixia/REBINYN or similar medicines, or if your body has developed a problem where it makes antibodies against Factor IX (called an "inhibitor"), you wouldn't be able to participate. If you have difficulties understanding or cooperating due to mental health issues, or a language barrier that can't be overcome, you wouldn't be eligible either.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Are you male?
  2. Do you have Haemophilia B?
  3. Are you currently using or about to start Refixia/REBINYN as regular treatment?
  4. Has your doctor already decided this treatment is right for you, separately from the study?
  5. Have you not previously taken part in this specific study?
  6. Are you able to understand the study information and agree to take part?
Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you'll continue with your regular treatment of Refixia/REBINYN, just as prescribed by your study doctor. Your clinic visits will be much like your usual appointments. During these visits, your doctor might do some routine tests if they think it's helpful.

They will also ask if you've had any side effects since your last visit. We'll ask you to keep a record of any bleeds you have, how you treat them, and when you take your regular Refixia/REBINYN dose. You'll also be asked to fill out questionnaires about how your Haemophilia B affects your daily life and your ability to be physically active.

Your participation in this study could last anywhere from 4 to 9 years, depending on when you start. Remember, you can choose to leave the study at any time, for any reason, without it affecting your medical care.

Potential risks and benefits

Participating in this study might not offer direct health benefits beyond the treatment you would already be receiving. However, the information gathered will be very valuable in helping doctors and researchers understand more about the long-term effects of Refixia/REBINYN for people with Haemophilia B. This improved understanding can lead to better care for others in the future. There are no additional medical risks from being in the study beyond those associated with your standard treatment and routine clinic visits. You have the right to withdraw from the study at any point, and doing so will not change the quality of your current or future medical care.

Locations (29)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • AKH - Klin. Abt. f. Haematologie u. Haemostaseologie
    Verified postcode
    Vienna, Austria
  • Cliniques universitaires Saint-Luc - Service Hématologie
    Verified postcode
    Brussels, Belgium
  • UZ Antwerpen - UZA - Kinderhemato-Oncologie
    Verified postcode
    Edegem, Belgium
  • UZ Leuven - Hart en Vaatziekten
    Verified postcode
    Leuven, Belgium
  • University of Calgary Cumming School of Medicine
    Verified postcode
    Calgary, Canada
  • Univ of Alberta Hospital Res
    Verified postcode
    Edmonton, Canada
  • CancerCare Manitoba
    Verified postcode
    Winnipeg, Canada
  • Health Science Centre
    Verified postcode
    St. John's, Canada
  • Hamilton Health Sciences Corp, Ontario
    Verified postcode
    Hamilton, Canada
  • Hamltn Hth Sci/McMstr Child Hosp
    Verified postcode
    Hamilton, Canada
  • The Hospital for Sick Children
    Verified postcode
    Toronto, Canada
  • KBC Zagreb, Rebro, Hemofilija centar
    Verified postcode
    Zagreb, Croatia

Common questions

What is Haemophilia B?

Haemophilia B is a health condition where your blood doesn't clot properly because you are missing a protein called Factor IX, leading to more bleeding.

What is Refixia/REBINYN?

Refixia/REBINYN is a medicine used to treat Haemophilia B by replacing the missing Factor IX, helping your blood clot better and preventing bleeds.

Will I get a different treatment in this study?

No, you will keep receiving the same Refixia/REBINYN treatment that your own doctor has already decided is best for you.

How long will I be in the study?

You could be in the study for 4 to 9 years, depending on when you start, but you can leave at any time.

Can I stop being in the study?

Yes, you can leave the study at any time for any reason, and it won't affect your medical care.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A Study Following Males With Haemophilia B on Prophylaxis Wi…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.